Skip to main content
ALT logo

ALT · Altimmune, Inc.

Track ALT — free
$1.41 +0.02 (+1.44%) At close · Nov 19
Market Cap
$274.37M
Shares
194.59M
Volume · Nov 19 4.3M Avg daily vol (3M) 3.96M

Price & Indicators

 

Key stats

Close
$1.41
Open
$1.40
Day range
$1.38–1.45
52-week closing range
$1.39–6.18
Average volume, 30 days
3.9M
Short interest
42.1M · 21.7% of shares · 12.2 days
Short volume, last session
56%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 12
Earnings call
Pemvidutide advances toward 2027 and 2029 milestones

Altimmune said pemvidutide's Phase III MASH trial has over 70 U.S. sites active, with 52-week data expected in 2029; an FDA meeting on AUD is scheduled for December, and RESTORE data are expected in the second half of 2027.

6 source passages
Our conviction in PEMVIDUTIDE is stronger than ever, coming out of ASLD's The Liver Meeting We already have over 70 U.S. sites activated we anticipate the PERFORMA 52-week data readout in 2029. our end of Phase II meeting with the FDA is scheduled for December We expect the top-line data for restore in the second half of 2027. valuable to Altimmune as we continue to advance. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PERFORMA enrollment begins; 52-week data expected in 2029

Altimmune began enrolling patients in the global PERFORMA Phase 3 trial evaluating pemvidutide in MASH; the 52-week data readout to support accelerated approval is anticipated in 2029.

Net loss $31.61M Diluted EPS -$0.15
Read from the MD&A section
3 source passages
Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. On August 3, 2026, we announced that we had begun enrolling patients in the PERFORMA Phase 3 trial, evaluating the efficacy and safety of pemvidutide in patients with MASH. The 52-week data readout from the PERFORMA trial to support the accelerated approval of pemvidutide is anticipated in 2029. Open the document at this passage
Nov 12
Current report 8-K
Phase 3 Advances With $480 Million Cash

Altimmune reported $480 million in cash, cash equivalents and investments as of September 30, 2026, and a net loss of $31.6 million, or $0.15 per share. PERFORMA Phase 3 progressed as planned, and an FDA End-of-Phase 2 meeting for AUD was scheduled for December 2026.

Financial results
4 source passages
$480 million in cash, cash equivalents and investments as of September 30, 2026 Net loss for the three months ended September 30, 2026, was $31.6 million, or $0.15 net loss per share The global PERFORMA Phase 3 MASH trial is progressing as planned An End-of-Phase 2 meeting with the FDA is scheduled for December 2026 to discuss the Phase 3 registrational program in AUD Open the document at this passage
Oct 29
Current report 8-K Events of Oct 27
$10.0 million draw extends interest-only period to June 1, 2028

Altimmune, Inc. drew $10.0 million after achieving clinical and financial milestones, extending its amortization date and interest-only period to June 1, 2028. The company must maintain qualified cash greater than or equal to 60% of outstanding term loan advances.

New debt or off-balance-sheet obligation
2 source passages
On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment to Loan and Security Agreement, dated as of November 5, 2025, the “Loan Agreement”), with Hercules Capital, Inc., and other lenders party thereto, which amount was made available upon achievement of certain clinical and financial milestones and subject to other terms and conditions set out in the Loan Agreement (the “Tranche 3 Milestone”). As a result of occurrence and satisfaction of the Tranche 3 Milestone, (i) the Amortization Date and interest-only period has been extended to June 1, 2028, and (ii) pursuant to the Minimum Cash covenant set forth in Section 7.19(a)(i) of the Loan Agreement, the Company shall maintain Qualified Cash in an amount greater than or equal to the outstanding principal amount of the Term Loan Advances multiplied by 60%. Open the document at this passage
Oct 27
Current report 8-K Events of Oct 23
Two New Directors Appointed; Three Directors to Retire in 2027

Altimmune's board appointed Peter Greenleaf and Alex Howarth as directors effective November 2, 2026, increasing its size from nine to eleven. John Gill, Mitchel Sayare and Klaus Schafer will retire from the board at the 2027 annual meeting.

Director or officer change, or executive pay, Regulation FD disclosure
2 source passages
the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors. As part of a planned transition process, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board and not stand for reelection at the end of their current one-year terms at the Company's 2027 Annual Meeting. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$41,000
Trailing 12 months
Net income (TTM)
−$104.35M
Trailing 12 months
Revenue growth YoY
+420.0%
Year over year
Operating margin
-230,461.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$230.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+129.6%
Year over year · more shares
Price change (1Y)
-69.3%
Trailing year
Short interest
21.7%
Latest settlement · 12.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Pemvidutide reported statistically significant AUD results and favorable MASH data, received key regulatory designations, and continued Phase 2 and Phase 3 development while cash runway extends through the expected 2029 PERFORMA readout. However, Q3 R&D, G&A and net loss increased year over year, AUD program timing remains unspecified, and development faces regulatory, manufacturing, enrollment and clinical execution risks.

Bullish
  • + The global PERFORMA Phase 3 trial is progressing as planned.
  • + RECLAIM produced statistically significant improvements in heavy drinking days and key FDA-registrational secondary measures.
  • + IMPACT showed concurrent improvements in liver fat, inflammation and fibrosis versus placebo.
  • + Cash burn is tracking to plan, with operating runway through the expected 2029 PERFORMA readout.
  • + An FDA end-of-Phase 2 meeting for the AUD Phase 3 program is scheduled for December 2026.
Bearish
  • − Q3 net loss increased to $31.6 million from $19.0 million year over year.
  • − Q3 R&D expense increased to $27 million from $15 million year over year.
  • − Q3 G&A expense increased to $8.7 million from $5.9 million year over year.
  • − Timing for the AUD program remains unspecified pending regulatory feedback.
  • − Development remains exposed to regulatory delays, manufacturing and supply-chain interruptions, site-access and enrollment risks, and clinical-trial execution risk.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −42%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −35%
trailing
6-month return −53%
trailing
YTD return −61%
this year
Relative strength −48%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +28 funds added
Insider flow Accumulating
Net +$96.4K over 90 days · 0% sells
Short interest Falling
21.65% of shares out · ▼ -0.2% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
194 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth +105%
Y/Y
EPS growth +25%
Y/Y
Free cash flow $-67.5M
Balance sheet $9.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −78%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +28 funds added
Insider flow Accumulating
Net +$96.4K over 90 days · 0% sells
Short interest Falling
21.65% of shares out · ▼ -0.2% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
194 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $6
vs 200-day avg -54% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALT
Altimmune, Inc.
this stock
$274.37M -60.9% +105.0% — 21.7%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
194
% held
73.2%
Net QoQ
-7.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Falling
Shares short
42.1M
Days to cover
12.2d
Change
-102.6K sh
View
Short Volume
Short vol %
56%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
11.4K
Value
$26.9K
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
52.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$96.4K
Buyers / Sellers
4 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$41.0K
Net income (FY)
$-88.1M
EPS diluted
$-1.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
23

Altimmune began enrolling patients in the global PERFORMA Phase 3 trial evaluating pemvidutide in MASH; the 52-week data readout to support accelerated approval is anticipated in 2029.

View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Altimmune Presents Positive Late-…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
ALT -12.4% -35.0% -53.2% -30.9% -60.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -7.0% -28.7% -47.5% -25.6% -65.9%
Key facts CIK 1326190 CUSIP 02155H200 13F (30d) 192 filings 176 filers Visit website Investor relations